+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Market Trajectory & Analytics

  • ID: 1244801
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Alcobra Ltd.
  • Curemark, LLC
  • Eli Lilly and Company
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $23.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$16.9 Billion in the year 2020, is projected to reach a revised size of US$23.8 Billion by 2027, growing at a CAGR of 5% over the period 2020-2027. Stimulant, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Stimulant segment is readjusted to a revised 6.6% CAGR for the next 7-year period.









The U.S. Market is Estimated at $5 Billion, While China is Forecast to Grow at 4.7% CAGR

The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Select Competitors (Total 27 Featured):
  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.
Frequently Asked Questions about the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics

What is the estimated value of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?

The Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics was estimated to be valued at $16.9 Billion in 2020.

What is the growth rate of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?

The growth rate of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics is 5.0%, with an estimated value of $23.8 Billion by 2027.

What is the forecasted size of the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?

The Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to be worth $23.8 Billion by 2027.

Who are the key companies in the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics?

Key companies in the Global Market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics include Alcobra Ltd., Amarantus Bioscience Holdings, Inc., Curemark, LLC, Eli Lilly and Company, Intellipharmaceutics International, Inc., Janssen Global Services, LLC, Mallinckrodt PLC, Mylan NV and Neurovance, Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alcobra Ltd.
  • Curemark, LLC
  • Eli Lilly and Company
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • ADHD Therapeutics: A Primer
  • Recent Market Activity
  • ADHD Therapeutics Market Outlook
  • Factors Driving ADHD Therapeutics Market
  • Changes in Insurance Coverage
  • Addition of Formal Guidelines
  • Low Diagnosis Threshold
  • Advancements in Field of Medicine
  • Unmet Needs
  • Launch of Pipeline Drugs
  • Factors Inhibiting ADHD Therapeutics Market
  • Side Effects Related to Use of Stimulants to Treat ADHD
  • Under-diagnosis of ADHD Condition
  • Reduced Availability of Non-Stimulants in Certain Geographies
  • Competitive Landscape
  • Major ADHD Medications Available in the Market
  • ADHD Medications Approved by FDA
  • Patent Validity for Major ADHD Drugs
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
  • Alcobra Ltd. (Israel)
  • Amarantus Bioscience Holdings, Inc. (US)
  • Amedra Pharmaceuticals LLC (US)
  • Curemark, LLC. (US)
  • Eli Lilly and Company (US)
  • Intellipharmaceutics International, Inc. (US)
  • Janssen Global Services, LLC (US)
  • Mallinckrodt PLC (Ireland)
  • Mylan N.V. (The Netherlands)
  • Neos Therapeutics, Inc. (US)
  • Neurovance, Inc. (US)
  • Noven Pharmaceuticals, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Supernus Pharmaceuticals, Inc. (US)
  • Tris Pharma, Inc. (US)

3. MARKET TRENDS & DRIVERS
  • Biological Psychiatry Gaining Ground
  • Social Media Drives Heightened Awareness
  • Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity
  • Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market
  • Strategic Alliances

4. GLOBAL MARKET PERSPECTIVE
  • III. MARKET ANALYSIS
  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • REST OF EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD

IV. COMPETITION
  • Total Companies Profiled: 27
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.
Note: Product cover images may vary from those shown